Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 3/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | LIPE | Q05469 | 3/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850172 | 0.94 | KDM1A (0.36) | KDM1AMAOBGCGRCHRM4LIPE | |
| SCHEMBL4848881 | 0.89 | GCGR (0.38) | GCGRCHRM4LIPECCR2MCHR1 | |
| SCHEMBL6478087 | 0.87 | GCGR (0.36) | GCGRCHRM4LIPEEPHX2CCR2 | |
| SCHEMBL6478251 | 0.86 | LIPE (0.37) | GCGRCHRM4LIPEEPHX2CCR2 | |
| SCHEMBL4849155 | 0.86 | SMPD3 (0.38) | GCGRLIPE | |
| SCHEMBL4845094 | 0.85 | LIPE (0.36) | GCGRLIPEEPHX2CCR2MCHR1 | |
| SCHEMBL6477360 | 0.84 | GCGR (0.35) | GCGRLIPEEPHX2 | |
| SCHEMBL6488797 | 0.83 | CCR2 (0.36) | GCGRLIPEEPHX2CCR2MCHR1 | |
| SCHEMBL4845087 | 0.83 | GCGR (0.36) | GCGRLIPE | |
| SCHEMBL6479033 | 0.82 | LIPE (0.33) | GCGRCHRM4LIPEEPHX2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | KDM1A 2002/4885MAOB 2394/4885GCGR 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.